Rosenson, Robert S <br/><br/>
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.  [electronic resource] 

 -  Cardiovascular drugs and therapy  06 2016 
 - 305-13 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1573-7241 
<br/><br/><label>Standard No.: </label>10.1007/s10557-016-6666-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--adverse effects<br/>Apolipoproteins B--blood<br/>Cholesterol--blood<br/>Double-Blind Method<br/>Ezetimibe--adverse effects<br/>Female<br/>Humans<br/>Hypercholesterolemia--blood<br/>Male<br/>Middle Aged<br/>PCSK9 Inhibitors<br/>Treatment Outcome<br/>Triglycerides--blood<br/>Young Adult